Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia

Kimberly J. Jenko, Jussi Hirvonen, Ioline D. Henter, Kacey B. Anderson, Sami S. Zoghbi, Thomas M. Hyde, Amy Deep-Soboslay, Robert B. Innis, Joel E. Kleinman

Research output: Contribution to journalArticlepeer-review


This study sought to determine whether cannabinoid-1 (CB1) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n=47) compared to controls (n=43). The CB1 receptor inverse agonist radioligand [3H]MePPEP was used to measure specific binding to CB1 receptors. The specific binding of [3H]MePPEP to CB1 receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [18F]FMPEP-d2 (80% statistical power, p<0.05).

Original languageEnglish (US)
Pages (from-to)185-188
Number of pages4
JournalSchizophrenia Research
Issue number2-3
StatePublished - Nov 2012


  • CB
  • Cannabinoid
  • Dorsolateral prefrontal cortex
  • Schizophrenia
  • [H]MePPEP

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Binding of a tritiated inverse agonist to cannabinoid CB<sub>1</sub> receptors is increased in patients with schizophrenia'. Together they form a unique fingerprint.

Cite this